

EDMOND - Elemental diet in bowel obstruction

Submission date 06/02/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/02/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 13/08/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-a-new-diet-for-women-with-a-blockage-in-the-bowel-edmond>

Contact information

Type(s)

Public

Contact name

Ms Eleanor Smith

ORCID ID

<https://orcid.org/0000-0002-9639-4862>

Contact details

Clinical Trials Office Room 07PGMO2
Department of Microbial & Cellular Sciences
Institute of Biosciences and Medicine
Leggett Building
Faculty of Health and Medical Sciences
Daphne Jackson Road
Guildford
United Kingdom
GU2 7WG
+44 1483 688547
eleanor.smith@surrey.ac.uk

Type(s)

Scientific

Contact name

Dr Agnieszka Michael

ORCID ID

<https://orcid.org/0000-0002-7262-6227>

Contact details

Department of Clinical and Experimental Medicine
Leggett Building
University of Surrey
Guildford
United Kingdom
GU2 7WG
+44 (0)1483 688546
a.michael@surrey.ac.uk

Additional identifiers**ClinicalTrials.gov (NCT)**

NCT03150992

Protocol serial number

32895

Study information**Scientific Title**

EDMONd – A feasibility study of Elemental Diet as an alternative to parenteral nutrition for patients with inoperable Malignant bowel Obstruction

Acronym

EDMONd

Study objectives

The aim of the study is to provide 'proof of concept' of Elemental Diet (ED) as an acceptable /useful feeding option for patients with inoperable bowel obstruction (IBO) and to examine the impact of ED on quality of life.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East Coast – Surrey Research Ethics Committee, 20/12/2016, ref: 16/LO/2079

Study design

Non-randomised; Interventional; Design type: Treatment, Dietary

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Specialty: Cancer, Primary sub-specialty: Gynaecological Cancers; UKCRC code/ Disease: Cancer/ Malignant neoplasms of female genital organs

Interventions

All participants receive the Elemental Diet (ED). The ED will be provided in the form of Elemental 028 Extra Liquid. Patients will be assessed by a clinician and specialist oncology dietician and given an individual plan of ED introduction. ED requires phased introduction to achieve tolerance of the course of 3-5 days, under the supervision of the study dietician. Following introduction of ED, patients will be discharged from the hospital (as per normal clinic practise) and followed up for 2 weeks. They will have a telephone follow up assessment once a week for two weeks. All other assessments will follow the standard of care. During the follow up assessment, patients will be assessed using the Memorial Symptom Assessment Scale and asked to complete a nutritional diary and Quality of Life questionnaires.

Intervention Type

Other

Primary outcome(s)

1. Taste acceptability of ED is measured on 1-5 grading in nutritional diary once per week for two weeks
2. Incidence of vomiting is measured on MSAS scale at day 1 of ED induction, discharge and once per week for two weeks
3. Incidence of pain is measured on MSAS scale at day 1 of ED induction, discharge and once per week for two weeks

Key secondary outcome(s)

1. The number (proportion) of patient who can tolerate ED following presentation with IBO and can subsequently be treated with palliative chemotherapy is measured by reviewing hospital case notes at patient completion of study
2. The number of patients alive at the end of the study is measured by reviewing hospital case notes at patient completion of study
3. Health Related Quality of Life is measured on EORTC-QLQ-C30 at day 1 of ED induction, discharge and once per week for two weeks
4. Nutritional Intake is measured by the number of ED cartons taken in 24 hours
5. Incidence of vomiting is measured on MSAS scale at day 1 of ED induction, discharge and once per week for two weeks

Completion date

31/12/2019

Eligibility

Key inclusion criteria

1. Age 18 years and over
2. Confirmed inoperable bowel obstruction due to disseminated malignancy
3. Ability to tolerate 500 ml of liquid
4. Capacity to give informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Bowel obstruction that can be managed with surgical intervention
2. Complete bowel obstruction and inability to tolerate small amount of liquid

Date of first enrolment

01/03/2017

Date of final enrolment

28/02/2019

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Surrey County Hospital

Egerton Road

Guildford

United Kingdom

GU2 7XX

Study participating centre

Royal Sussex County Hospital

Eastern Road

Brighton

United Kingdom

BN2 5BE

Study participating centre
Guy's Hospital
Great Maze Pond
London
United Kingdom
SE1 9RT

Sponsor information

Organisation
Royal Surrey County Hospital NHS Foundation Trust

ROR
<https://ror.org/050bd8661>

Funder(s)

Funder type
Charity

Funder Name
Target Ovarian Cancer

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	version V2	04/01/2017	20/02/2017	No	Yes
Poster results	results presented in poster at the European Society for Gynaecological Oncology in (ESGO)	14/12/2020	13/08/2021	No	No